Pityriasis rosea Associated with Imatinib (STI571, Gleevec)

Konstantopoulos, Kostas; Papadogianni, A.; Dimopoulou, Maria; Kourelis, C.; Meletis, John

doi:10.1159/000063900

Cited by 42 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Imatinib may emerge as the mainstay treatment for CML. To date, imatinib has been reported to cause maculopapular rash, exfoliative dermatitis [1], AGEP [3], erosive lichenoid reaction [4] and pityriasis rosea [5]. Most of the cutaneous side effects of imatinib seem to be dose related; we believe continued treatment with low doses of imatinib 400 mg/day (as in our patient) eventually results in resolution of the rash.…”

supporting

confidence: 52%

Imatinib (STI-571)-Induced Exfoliative Dermatitis in a Saudi Patient with Deck Chair Sign

Banka¹,

Aljurf

Hamadah³

2003

Dermatology

View full text Add to dashboard Cite

supporting

confidence: 52%

Imatinib (STI-571)-Induced Exfoliative Dermatitis in a Saudi Patient with Deck Chair Sign

Banka¹,

Aljurf

Hamadah³

2003

Dermatology

View full text Add to dashboard Cite

“…The mechanism of c-Met activation by imatinib is unknown and the role of EGFR in this process was not studied. Aberrant activation of multiple signaling cascades may be associated with the clinical toxicity of imatinib that has been described in some patients (Ebnoether et al, 2002;Esmaeli et al, 2002;Hsiao et al, 2002;Konstantopoulos et al, 2002;Schwarz et al, 2002;Vidal et al, 2002) and the appearance of new and the progression of existing squamous epithelial cancers in patients treated with imatinib for CML1 (Baskaynak et al, 2003). Interestingly, EGF can disrupt Fig.…”

Section: Discussionmentioning

confidence: 99%

“…For example, imatinib causes skin inflammation in some patients and peripheral and cerebral edema in others (Ebnoether et al, 2002;Hsiao et al, 2002;Konstantopoulos et al, 2002;Schwarz et al, 2002). Rapid progression of squamous cutaneous epithelial cell carcinoma has also been reported in patients treated with imatinib 1 (Baskaynak et al, 2003).…”

mentioning

confidence: 99%

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells

2005

View full text Add to dashboard Cite

Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib. Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of imatinib-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (EGFR) activation. Imatinib-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of EGFR in this process. Western blot analysis of cells incubated with imatinib demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2. An in vitro kinase assay showed that imatinib did not directly affect EGFR kinase activity, suggesting involvement of EGFR-activating molecules. Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced imatinib-mediated mitogen activated protein kinase (MAPK) activation. Imatinib stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation. Together, these results suggested that imatinib affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands. Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors. This finding demonstrates the need for careful use of this drug in cancer patients.

show abstract

“…Treatments for malignancies might also lead to focal (22) or generalised (23, 24) PR-like eruptions. Chemotherapy for malignancies have also been reported to lead to classical PR (25).…”

Section: Malignanciesmentioning

confidence: 99%

The first reported patient with non-Hodgkin lymphoma presenting as pityriasis rosea

Chuh¹

2015

cderm

View full text Add to dashboard Cite

SummaryBackground. Owing to the spontaneous remission with no complication being the rule, pityriasis rosea (PR) has been termed Doctor's Delight. Only two patients have been reported to have Hodgkin lymphoma and atypical PR concomitantly. There exists no report on the association of PR and non-Hodgkin lymphoma. Case report. We present a 62-year-old male patient with fever and coryzal symptoms, followed by a herald patch at the right inferior quadrant of his anterior abdominal wall. One week later, generalised skin lesions erupted on his trunk and proximal aspects of his four limbs. We saw him 12 days after onset of the primary patch. Examination revealed clinical features entirely compatible with classical PR. Systemic examination revealed enlarged and firm inguinal lymph nodes bilaterally. Spontaneous rash resolution occurred two weeks later. As the inguinal lymph nodes were still enlarging over time, we referred him to a physician. Lymph node biopsy revealed non-Hodgkin lymphoma. Discussion. This is the first reported patient with non-Hodgkin lymphoma presenting as classical PR. PR in the elderlies, pregnant women, people with autoimmune diseases or tendencies, people after organ transplantation, and immunocompromised people might be at a higher risk of serious underlying diseases or severe complications, and are important exceptions for this Doctor's Delight.

show abstract

Pityriasis rosea Associated with Imatinib (STI571, Gleevec)

Cited by 42 publications

References 10 publications

Imatinib (STI-571)-Induced Exfoliative Dermatitis in a Saudi Patient with Deck Chair Sign

Imatinib (STI-571)-Induced Exfoliative Dermatitis in a Saudi Patient with Deck Chair Sign

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells

The first reported patient with non-Hodgkin lymphoma presenting as pityriasis rosea

Contact Info

Product

Resources

About